https://www.nejm.org/doi/10.1056/NEJMoa2304748
In a trial, 661 patients with complicated UTI were randomized to receive cefepime–taniborbactam or meropenem. Of 436 in the microITT population, 70.6% on cefepime–taniborbactam vs. 58.0% on meropenem achieved composite success, showing superior efficacy (P=0.009). Safety profiles were similar.
![](https://static.wixstatic.com/media/e4917c_68b7f085c76f4242adb491c491d82689~mv2.jpg/v1/fill/w_147,h_200,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/e4917c_68b7f085c76f4242adb491c491d82689~mv2.jpg)